“Informed by the central role of the NLRP3 inflammasome in the gout flare, trials of IL-1 inhibitors, such as anakinra and canakinumab, have shown efficacy in treating gout flares,” Dr. Dalbeth explains. “Treatment with canakinumab, the long-acting human anti-IL-1β monoclonal antibody, also prevents recurrent gout flares.
“NLRP3 inflammasome inhibitors have been investigated for gout flare treatment in early phase development; the clinical efficacy and safety of these agents is not yet established,” concludes Dr. Dalbeth.
Katie Robinson is a medical writer based in New York.
Disclosures
Dr. Dalbeth has received consulting fees, speaker fees or grants from Novartis, Horizon, Selecta, Arthrosi, LG Chem, JPI, PTC Therapeutics, Protalix, Unlocked Labs, Hikma, Dexcel Pharma, Shanton Pharma, Sobi, Avalo, BioMarin, Crystalys and MedCryst, outside the submitted work.
References
- Bucala R, Solomon DH. Immunology for the rheumatologist: Arthritis & Rheumatology introduces a new problem-based immunology review series with great educational potential. Arthritis Rheumatol. 2024 Jan;76(1):9–10.
- Poulsen R, Dalbeth N. Gout and NLRP3 inflammasome biology. Arthritis Rheumatol. Published online May 5, 2025. doi:10.1002/art.43215
